Last updated on January 2020

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Brief description of study

This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.

Clinical Study Identifier: NCT04153149

Find a site near you

Start Over

Clinical Trial Site

La Mesa, CA United States
  Connect »